| Literature DB >> 35468754 |
Morris Ogero1,2,3, James Orwa4, Rachael Odhiambo4,5, Felix Agoi4, Adelaide Lusambili4, Jerim Obure6, Marleen Temmerman6,7,8, Stanley Luchters4,8,9,10, Anthony Ngugi4.
Abstract
BACKGROUND: There is substantial evidence that immunization is one of the most significant and cost-effective pillars of preventive and promotive health interventions. Effective childhood immunization coverage is thus essential in stemming persistent childhood illnesses. The third dose of pentavalent vaccine for children is an important indicator for assessing performance of the immunisation programme because it mirrors the completeness of a child's immunisation schedule. Spatial access to an immunizing health facility, especially in sub-Sahara African (SSA) countries, is a significant determinant of Pentavalent 3 vaccination coverage, as the vaccine is mainly administered during routine immunisation schedules at health facilities. Rural areas and densely populated informal settlements are most affected by poor access to healthcare services. We therefore sought to determine vaccination coverage of Pentavalent 3, estimate the travel time to health facilities offering immunisation services, and explore its effect on immunisation coverage in one of the predominantly rural counties on the coast of Kenya.Entities:
Keywords: Geographical accessibility; Pentavalent; Travel time
Mesh:
Substances:
Year: 2022 PMID: 35468754 PMCID: PMC9040218 DOI: 10.1186/s12889-022-12570-w
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 4.135
Fig. 1Map of Kaloleni-Rabai Subcounties where the Community Health Demographic Surveillance System is implemented. Source of map: generated by the author using open-source software QGIS v3.12
Fig. 2Map showing the distribution of households with children aged < 11 months in the study area. Source of map: generated by the author using open-source software QGIS v3.12
Characteristics of the children 14 weeks to 11 months eligible for pentavalent vaccination
| Gender (Female) | 1743 (50.7%) | 518 (51.4%) | 2,261 (51.0%) |
| Age in months median (IQR) | 7.3(5.6–9.0) | 7.7(5.4–9.4) | 7.4(5.5–9.1) |
| Travel time (minutes) to facility (median IQR) | 39(16–63) | 47(25–72) | 41(18–65) |
| Peri-urban area of residence | 1,189 (34.6%) | 223 (22.1%) | 1,412 (31.8%) |
| Use safe water | 1331 (38.7%) | 328 (32.6%) | 1,659 (37.3%) |
| Treats drinking water | 1959 (57.0%) | 519 (51.5%) | 2,478 (55.8%) |
| Hand-washing facility in a household | 1174 (34.2%) | 355 (35.3%) | 1,529 (34.4%) |
| Ownership of latrine/toilet by a household | 2143 (62.4%) | 576 (57.2%) | 2,719 (61.2%) |
| Has a birth certificate | 159 (4.6%) | 62 (6.2%) | 221 (5.0%) |
| Is an orphan | 67 (2.0%) | 26 (2.6%) | 93 (2.1%) |
| Sleep under mosquito-treated net | 3247 (94.5%) | 889 (88.3%) | 4,136 (93.1%) |
| More than 1 h travel time | 959 (27.9%) | 375 (37.2%) | 1,334 (30.1%) |
Fig. 3Vaccination coverage over the rounds of data collection in the community demographic surveillance system
Fig. 4Vaccination coverage across community health units participating in the demographic surveillance system
Fig. 5Distribution of the mean travel time from each grid (30 × 30 m) to the nearest immunizing health facility (red cross). The travel time was composite of walking and motorized transport to the nearest immunizing health facility in the study area. Source of map: generated by the author using open-source software QGIS v3.12
Fig. 6Travel time in different populations (vaccinated vs not vaccinated) across community health units participating in the demographic surveillance system
Multivariate model for factors influencing Pentavalent 3 vaccination coverage
| Urban area of residence (Urban) | 1.02 (0.73 – 1.44) |
| Treats drinking water | 1.09 (0.97 – 1.21) |
| Hand-washing facility in a household | 0.82 (0.74 – 0.92) a |
| Ownership of latrine/toilet by a household | 1.04 (0.93 – 1.17) |
| Has a birth certificate | 1.27 (1.00 – 1.61) a |
| Is an orphan | 0.80 (0.59 – 1.10) |
| Child sex (Male) | 1.01 (0.93– 1.11) |
| Sleep under mosquito-treated net | 1.36 (1.13 – 1.65) a |
| Given vitamin A supplements | 6.41 (5.82 – 7.07) a |
| More than 1 h travel time | 0.84 (0.75 – 0.94) a |
adenotes statistical significance at the 5% significance level